Breaking News
RBC Capital Analyst Lowers Price Target for BlackBerry Reflecting Cautious Outlook
On February 14, 2024, RBC Capital analyst Paul Treiber made a noteworthy move regarding BlackBerry (NYSE: BB). Despite maintaining a...
Alteryx and Databricks Join Forces to Accelerate AI Adoption in Enterprises
On February 14, 2024, Alteryx, Inc. made an exciting announcement about their expanded partnership with Databricks. This collaboration aims to...
Deere Companys Earnings Report and Stock Performance Analysis
On February 15, 2024, Deere & Company (NYSE:DE) is set to unveil its latest quarterly earnings report, with analysts predicting...
Anticipation Builds for Shake Shacks Quarterly Earnings Report
On February 14, 2024, Shake Shack (NYSE:SHAK) is set to unveil its quarterly earnings report, which is highly anticipated by...
Anticipation and Optimism Surround Procore Technologies Upcoming Earnings Report
On February 14, 2024, Procore Technologies (NYSE:PCOR) is set to unveil its latest quarterly earnings report, which is expected to...
Atara Biotherapeutics Submits IND Application for Revolutionary Therapy to Treat Lupus Nephritis
On February 14, 2024, Atara Biotherapeutics made a groundbreaking move by submitting an Investigational New Drug (IND) application to the...
Analysts Remain Positive on IPG Photonics Despite Slight Decrease in Price Target
As of February 14, 2024, analysts are expressing a positive outlook on IPG Photonics (NASDAQ:IPGP), despite a slight decrease in...
Inspira Technologies Secures Groundbreaking US Patent Approval for VORTX Revolutionizing Medical Oxygenation
On February 14, 2024, Inspira Technologies, a renowned medical technology company, achieved a groundbreaking milestone by securing the very first...
Trading Halts and Resumptions Maintaining Order in the Market
On February 14, 2024, a trading halt will temporarily suspend all trading activities for a security or securities at various...
Analyst at Cantor Fitzgerald Reiterates Neutral Rating and 128 Price Target for Sarepta Therapeutics NASDAQ SRPT
On February 14, 2024, Kristen Kluska, an analyst at Cantor Fitzgerald, expressed her opinion on Sarepta Therapeutics (NASDAQ: SRPT), reiterating...
Popular News
-
SunHydrogen Set for European Debut with Groundbreaking Technology
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
-
Synopsys Shares Plummet Amid Fraud Allegations and Disappointing Earnings
